FDA Shuffles Animal Meds List for Clarity
Published Date: 5/9/2025
Rule
Summary
The FDA just updated the rules for new animal drugs approved in early 2025, making sure everything is clear and up-to-date. This affects drug makers, vets, and pet owners by confirming which new medicines are officially good to go. The changes kick in right away on May 9, 2025, with no extra costs but better info and transparency for everyone.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
New sirolimus product for cats
FDA added Sec. 516.2106 for sirolimus: sustained‑release tablets containing 0.4, 1.2, or 2.4 mg sirolimus are specified, and the drug is approved for use in cats for management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM). The label directs oral administration once weekly at 0.3 mg per kilogram of bodyweight and identifies sponsor number 086169.
FDA approves two generic animal drugs
FDA approved two generic animal drug applications during January–March 2025: EPRIMECTIN Pour‑On (eprinomectin) as a generic copy of NADA 141-079 (file no. 200-626) on January 13, 2025, and tulathromycin injectable solution as a generic copy of NADA 141-244 (file no. 200-742) on February 25, 2025.
Withdrawal of SEDAZINE (xylazine) approval
Approval of ANADA 200-088 for SEDAZINE (xylazine hydrochloride) Injectable Solution was withdrawn at the sponsor's request because the product is no longer manufactured or marketed; the withdrawal was effective December 10, 2023. The record and animal drug regulations are amended to reflect this withdrawal.
Approval documents and reviews posted online
For approvals during January, February, and March 2025 that required safety/effectiveness review or environmental review, FDA states that documentation (NEPA reviews) and FOIA Summaries, along with marketing exclusivity and patent information, may be obtained at Animal Drugs @ FDA: https://animaldrugsatfda.fda.gov/adafda/views/#/search.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-08129, Federal Management Regulation; Nondiscrimination Clarification in the Federal Workplace; Rescission
Starting May 9, 2025, the government is canceling a 2016 rule that said federal workplaces must protect people from discrimination based on gender identity. This change affects all federal employees and means the government will now focus only on biological sex in discrimination rules. No new costs or deadlines come with this update, but it shifts how gender discrimination is understood in federal jobs.
Next: 2025-08143, Medical Devices; Immunology and Microbiology Devices; Classification of the DNA-Based Test To Measure Minimal Residual Disease in Hematological Malignancies
The FDA is officially putting the DNA-based test that checks for tiny amounts of leftover cancer cells in blood cancers into a safer, easier-to-manage category called Class II. This change helps make sure the test is safe and works well while making it simpler for companies to get it to patients faster. The new rules started on May 9, 2025, and could speed up access to this important test without extra costs.